A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer

被引：0
|
作者：
Heather Wakelee
George A. Fisher
机构：
[1] Stanford Clinical Cancer Center,
来源：
Investigational New Drugs | 2005年 / 23卷
关键词：
amifostine; irinotecan; phase I; colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：241 / 242
页数：1
相关论文
共 50 条
  • [21] Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment with irinotecan (CPT-11)
    Boisseau, M
    Bugat, R
    Mahjoubi, M
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (04) : 737 - 738
  • [22] Irinotecan (CPT-11) pretreated metastatic colorectal cancer (CRC):: A single institution experience.
    Fernández, Y
    Lara, MA
    Salinas, P
    Alonso, ML
    García-Girón, C
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S12 - S12
  • [23] Phase I trial of Exisulind (Aptosyn™) and CPT-11 in patients with colorectal cancer and other solid tumors.
    Marshall, JL
    Park, S
    Al-Sayed, A
    Fox, E
    Rizvi, N
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3713S - 3713S
  • [24] Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU):: A phase II study
    Antón, A
    Aranda, E
    Carrato, A
    Marcuello, E
    Massutti, B
    Cervantes, A
    Abad, A
    Sastre, J
    Fenández-Martos, C
    Gallén, M
    Díaz-Rubio, E
    Huarte, L
    Balcells, M
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (08): : 639 - 643
  • [25] Irinotecan (CPT-11) as first line treatment of patients with not pretreated advanced colorectal cancer
    Firyida, JL
    Menendez, MD
    Mel, JR
    Diz, P
    Constenla-Figueiras, M
    Casal, J
    Valladares, M
    Castellanos, J
    Balcells, M
    ANNALS OF ONCOLOGY, 1998, 9 : 38 - 39
  • [26] Phase II trial of irinotecan (CPT-11) and radiation followed by irinotecan and BCNU in glioblastoma patients (pts).
    Ballman, K. V.
    Jaeckle, K. A.
    Schomberg, P.
    Giannini, C.
    Galanis, E.
    Brown, P.
    Arusell, R.
    Reid, J.
    Hammack, J.
    Buckner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 73S - 73S
  • [27] Phase I dose finding study with irinotecan (CPT-11) in cancer patients (pts) with hepatic dysfunction
    Raymond, E
    Vernillet, L
    Boige, V
    Hua, A
    Ducreux, M
    Mekhaldi, S
    Jacques, C
    Gatineau, M
    Mignard, D
    Vergniol, JC
    Armand, JP
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S283 - S284
  • [28] Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation
    Cunningham, D
    EUROPEAN JOURNAL OF CANCER, 1996, 32A : S1 - S8
  • [29] Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Watanabe, M.
    Matsui, N.
    Kusano, M.
    ONCOLOGY, 2009, 77 (3-4) : 192 - 196
  • [30] Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy
    García-Girón C.
    Palomo A.G.
    López C.A.
    Carbonero A.L.
    Ureña M.M.
    Cebrián E.A.
    Galíndez R.B.
    Yustos M.A.
    Gallego J.A.
    Clinical and Translational Oncology, 2005, 7 (6) : 244 - 249
12345